Increased Short‐term and Long‐term Mortality in Community‐ and Hospital‐acquired Hypernatremia and in Patients with Delayed Serum Sodium Correction

2021 ◽  
Author(s):  
Charat Thongprayoon ◽  
Wisit Cheungpasitporn ◽  
Tananchai Petnak ◽  
Jing Miao ◽  
Qi Qian
Keyword(s):  
Serum Sodium ◽  
Short Term ◽  
Sodium Correction ◽  
Hospital Acquired ◽  
Long Term Mortality

Abstract P290: Short-term Weight Change and Long-term Mortality in the Trials of Hypertension Prevention

Circulation ◽  
2016 ◽  
Vol 133 (suppl_1) ◽  
Author(s):  
Nancy R Cook ◽  
Lawrence J Appel ◽  
Paul K Whelton
Keyword(s):  
Weight Loss ◽  
Weight Change ◽  
Phase 1 ◽  
Total Mortality ◽  
Weight Loss Intervention ◽  
Phase 2 ◽  
Short Term ◽  
Hypertension Prevention ◽  
Long Term Mortality

Introduction: Although weight loss has favorable effects on intermediate outcomes, such as blood pressure and insulin resistance, few studies have examined its effects on long-term outcomes including total mortality. Methods: In the Trials of Hypertension Prevention (TOHP) individuals aged 30-54 years with high normal BP were randomized to a weight loss intervention, to one of several other lifestyle or dietary supplement interventions, or to usual care. All participants from Phase 1 (1987-90) and Phase 2 (1990-5) were followed for mortality through 2013. The association of weight change during any of the interventions with long-term mortality up to 18-24 years after the trial periods was examined among 3828 participants who fell into a high baseline weight stratum, defined as body mass index at least 26 kg/m2 in men and 24 kg/m2 in women. Results and Conclusions: There were 1477 high-weight participants in Phase 1 and 2351 in Phase 2, of whom 21% and 50%, respectively, were assigned to a weight loss intervention. Overall, mean weight change during the trial period was -1.8 lbs (-0.8% of baseline body weight) over 1.5 years in Phase 1 and 1.6 lbs (0.8%) over 3-4 years in Phase 2. A total of 556 (15%) lost > 5%, 1,101 (29%) lost <=5%, 1,567 (41%) gained less than 5%, and 604 (16%) gained > 5% in body weight. Corresponding hazard ratios (HRs) for total mortality were 0.82 (95% confidence interval (CI)=0.57-1.18), 0.94 (95% CI=0.72-1.23), 1.00 (reference), and 1.29 (95% CI=0.92-1.80) (p-trend = 0.046). There was a direct linear relationship with percent change in weight during the trial period and later mortality (HR=1.14 per 5% change, 95% CI=1.02-1.28, p=0.019). This association persisted throughout the course of mortality follow-up (Figure). In these healthy individuals taking part in lifestyle and nutrition supplement trials , short-term weight change was directly associated with mortality about two decades later. These results are consistent with a long-term beneficial effect of presumed intentional weight loss on total mortality.

Tu1686 PRE-TIPS SARCOPENIA IS ASSOCIATED WITH SHORT-TERM BUT NOT LONG-TERM MORTALITY IN PATIENTS WITH CIRRHOSIS.

2020 ◽  
Vol 158 (6) ◽  
pp. S-1452-S-1453
Author(s):  
Ahmed Ouni ◽  
wei zhang ◽  
Walid Khan ◽  
Blake A. Thompson ◽  
Nabeel Moon ◽  
...  
Keyword(s):  
Short Term ◽  
Long Term Mortality

scholarly journals Comparison of Prognostic Accuracy of the quick Sepsis-Related Organ Failure Assessment between Short- & Long-term Mortality in Patients Presenting Outside of The Intensive Care Unit - A Systematic Review & Meta-analysis

2018 ◽  
Author(s):  
TOH LEONG TAN ◽  
Ying Jing Tang ◽  
Ling Jing Ching ◽  
Noraidatulakma Abdullah ◽  
Hui-min Neoh
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Short Term ◽  
Suspected Infection ◽  
Failure Assessment ◽  
Short Term Mortality ◽  
Short And Long Term ◽  
Qsofa Score ◽  
Long Term Mortality

Objective: In year 2016, quick Sepsis-Related Organ Failure Assessment (qSOFA) was introduced as a better sepsis screening tool compared to systemic inflammatory response syndrome (SIRS). The purpose of this systematic review and meta-analysis is to evaluate the ability of the qSOFA in predicting short- and long-term mortality among patients outside the intensive care unit setting. Method: Studies reporting on the qSOFA and mortality from MEDLINE (published between 1946 and 15th December 2017) and SCOPUS (published before 15th December 2017). Hand-checking of the references of relevant articles was carried out. Studies were included if they involved inclusion of patients presenting to the ED; usage of Sepsis-3 definition with suspected infection; usage of qSOFA score for mortality prognostication; and written in English. Study details, patient demographics, qSOFA scores, short-term (<30 days) and long-term (≥30 days) mortality were extracted. Two reviewers conducted all reviews and data extraction independently. Results and Discussion: A total of 39 studies met the selection criteria for full text review and only 36 studies were inclided. Data on qSOFA scores and mortality rate were extracted from 36 studies from 15 countries. The pooled odds ratio was 5.5 and 4.7 for short-term and long-term mortality respectively. The overall pooled sensitivity and specificity for the qSOFA was 48% and 85% for short-term mortality and 32% and 92% for long-term mortality, respectively. Studies reporting on short-term mortality were heterogeneous (Tau=24%, I2=94%, P<0.001), while long-term mortality studies were homogenous (Tau=0%, I2<0.001, P=0.52). The factors contributing to heterogeneity may be wide age group, various clinical settings, variation in the timing of qSOFA scoring, and broad range of clinical diagnosis and criteria. There was no publication bias for short-term mortality analysis. Conclusion: qSOFA score showed a poor sensitivity but moderate specificity for both short and long-term mortality prediction in patients with suspected infection. qSOFA score may be a cost-effective tool for sepsis prognostication outside of the ICU setting.

Short-term and long-term mortality following pediatric intensive care

2012 ◽  
Vol 54 (2) ◽  
pp. 248-255 ◽  
Author(s):  
Eleni A Volakli ◽  
Maria Sdougka ◽  
Vasiliki Drossou-Agakidou ◽  
Maria Emporiadou ◽  
Melpomeni Reizoglou ◽  
...  
Keyword(s):  
Intensive Care ◽  
Pediatric Intensive Care ◽  
Short Term ◽  
Long Term Mortality

AML-294: Predictors of Short-Term and Long-Term Mortality in Leukemia Patients with Neutropenic Fever

2020 ◽  
Vol 20 ◽  
pp. S199-S200
Author(s):  
Quang Nguyen ◽  
Amitoj Gill ◽  
Rani Jayswal ◽  
Richard O'Neal ◽  
Heidi Weiss ◽  
...  
Keyword(s):  
Neutropenic Fever ◽  
Short Term ◽  
Long Term Mortality

P1520Management and outcome of women with NSTEMI. Have there been any changes in recent years?

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
C Cacho ◽  
T Gonzalez Ferrero ◽  
A Torrelles Fortuny ◽  
M Perez Dominguez ◽  
C Abbou Johk ◽  
...  
Keyword(s):  
P Value ◽  
Evidence Based ◽  
Short Term ◽  
Killip Class ◽  
Hospitalization Period ◽  
Short Term Mortality ◽  
Baseline Characteristics ◽  
Long Term Mortality

Abstract Introduction Women have been less represented in every NSTEMI clinical trial. Moreover, it has been observed that this group of patients have usually received less revascularization and evidence based treatment, therefore presenting with a greater long and short-term mortality. Purpose The purpose of our study is to analyze the presence of differences in baseline characteristics, management and outcome of women with NSTEMI during the last decade. Methods and results Retrospective study including 861 women admitted for NSTEMI between 2003 and 2015 in our center. We divided 2 groups according to hospitalization period (2003–2008 and 2009–2015) with a medium follow up of 4.5±2.9 years. Baseline characteristics and treatment at discharge are described on table 1. We noticed a greater use of statins and ACEI/ARB on the second period as well as a greater percentage of patients receiving early revascularization. It is remarkable on women a non-significant reduction of heart failure hospitalization at follow up (6.8% vs 4.5%; p=0.091), neither differences on 30-day mortality (1.3% vs 0,4%) or 1-year mortality (7.1% vs 5.8%). However, long-term mortality for the second group is reduced (HR 0.69; CI 95% 0.52–0.89), even after performing a multivariate analysis (HR 0.64; CI 95% 0.48–0.85). Characteristic Population (n=861) 2003–2008 (n=395) 2009–2015 (n=466) p-value Age (years) 73±12 73±12 72±12 0.316 Hypertension 629 (73.1%) 285 (72.2%) 344 (73.8%) 0.318 Hypercholesterolemia 414 (48.1%) 190 (48.1%) 224 (48.1%) 0.523 Killip class 0.292   I 664 (77.1%) 299 (75.7%) 365 (78.3%)   II 143 (16.6%) 74 (18.7%) 69 (14.8%)   III 47 (5.5%) 20 (5.1%) 27 (5.8%)   IV 4 (0.5%) 2 (0.5%) 2 (0.4) GRACE score 129±32 130±37 128±33 0.897 Early PCI 249 (29.3%) 76 (19.2%) 173 (38.0%) <0.005 Treatment at discharge   AAS 698 (81.1%) 313 (79.2%) 385 (82.6%) 0.120   Clopidogrel 465 (54.0%) 221 (55.9%) 244 (52.4%) 0.162   ACEI/ARB 466 (54.1%) 191 (48.4%) 275 (59.0%) 0.001   Beta-blocker 509 (59.1%) 238 (60.3%) 271 (58.2%) 0.290   Statins 643 (74.7%) 275 (69.6%) 368 (79.0%) 0.001 Conclusions In recent years, early interventionist management and greater use of evidence-based therapies have been observed in women with NSTEMI. This has been associated with a lesser long-term mortality, although short-term events have remained the same.

Sign in / Sign up

Export Citation Format

Share Document